Eyeworld

OCT 2017

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/880217

Contents of this Issue

Navigation

Page 141 of 150

Gati-Dex* (Gatifloxacin 0.5%, Dexamethasone 0.1%) The New Kid On The Block: Come See Us About Our Show Special AAO 2017 booth 4020 844.446.6979 *For professional use only. ImprimisRx specializes in customizing medications to meet unique patient and practitioner needs. All formulations are sold in accordance with state and federal regulations, which may vary. ImprimisRx dispenses these formulations only to individually identified patients with valid prescriptions. No compounded medication is reviewed by the FDA for safety or efficacy. ImprimisRx does not compound copies of commercially available products. References available upon request. ImprimisRx is a registered trademark of Imprimis Pharmaceuticals. ©2017 Imprimis Pharmaceuticals, Inc. All Rights Reserved. IMPO0183 09/17 IMPRIMIS PROVIDES STERILE COMPOUNDED FORMULATIONS YOU CAN TRUST Meets requirements under the Section 503B of the FD&C Act Manufactured with components of FDA-registered manufacturers Release and stability testing performed at FDA-registered labs Sterility, endotoxin and potency testing performed on each batch Continuous environmental monitoring to maintain product quality standards

Articles in this issue

Archives of this issue

view archives of Eyeworld - OCT 2017